NeuroBell
UCC spinout building a portable neonatal EEG monitor with embedded AI seizure detection for bedside use in NICUs.
What They Do
NeuroBell is developing NeuroBell Luna, a portable wireless EEG system intended to detect neonatal seizures in real time without requiring constant specialist interpretation. The product is designed for bedside use by ordinary NICU teams, with on-device or edge-AI processing positioned as a faster and simpler alternative to conventional continuous EEG workflows. Public materials suggest a classic medtech business model selling into hospitals and neonatal units rather than a reimbursement- or employer-driven service model. The company is still early, but it is already ISO 13485-certified and has framed FDA submission and clinical validation as the core path to commercialization.
Competitive Position
NeuroBell competes most directly with cergenx and the neonatal product expansion at ceribell, all of which are trying to reduce the specialist bottleneck around newborn EEG interpretation. Its main differentiators are portability, wireless deployment, and an edge-AI architecture built specifically for neonatal seizure detection from the start. That focus could fit lower-resource or smaller NICU environments well, but the company is much earlier than Ceribell and still pre-clearance.
Funding Rounds
No funding rounds on record for this company.